奥浦迈14.5亿元并购案再遭独董反对，标的公司估值增值率56.62%

Group 1 - The independent director of Aopumai, Tao Hua'an, opposed the company's acquisition of 1.45 billion yuan, stating that the company does not currently have a necessity for mergers and acquisitions [1][2] - This marks the fourth time Tao has voted against acquisition-related proposals during board meetings [1] - Aopumai plans to acquire control of Pengli Biotechnology, which specializes in preclinical CRO services, with a final transaction price of approximately 1.45 billion yuan, reflecting a valuation increase of 56.62% [1] Group 2 - Post-acquisition, Aopumai expects to add 555 million yuan in goodwill, which would account for 849.41% of the projected net profit for 2024 [2] - The CRO industry is characterized by intense competition and significant market segmentation, with risks of price wars and regulatory impacts [2] - Aopumai reported revenue of approximately 272 million yuan for the first three quarters of the year, representing a year-on-year growth of 25.79%, and a net profit of about 49.43 million yuan, up 81.48% year-on-year [2]